MetaCap

VolitionRX Limited (VNRX)

NYSE: VNRXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

0.1621-0.0026 (-1.58%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VNRX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.57
52-week range
0.1555 – 7.80
Day range
0.1555 – 0.17
Volume / Avg
1.20M / 9.57M
Beta
—

52-week range

$0.1555$7.80

VNRX stock today

Shares of VolitionRX (VNRX) finished lower on Nov 20 at $0.1621, a drop of 1.58% or $0.0026 per share, versus the S&P 500's 3.70% decline. Trading was light, with 1.20M shares changing hands, about 13% of the average daily volume. At this level, VNRX sits near the bottom of its 52-week range of $0.1555 to $7.80: 97.9% below the high and 4.2% above the low.

VolitionRX has posted a net loss over the last twelve months (EPS of -$2.57), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About VolitionRX

Company profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. Cameron Reynolds MBA
Headquarters
Henderson, NV
Employees
57
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, VolitionRX generated $1.7 million in revenue, up 40.0% from fiscal 2024, its 5th consecutive year of revenue growth. VolitionRX reported a net loss of $23.4 million, compared with a loss of $27.0 million a year earlier. Operating margin was -1258.5%.

VolitionRX annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.73M$1.23M$775.30K$306.39K$90.03K
Growth+40.04%+59.10%+153.04%+240.30%+570.25%
Net income$-23.36M$-26.97M$-35.68M$-30.60M$-26.99M
EPS (diluted)—$-0.31$-0.50—$-0.51

Analyst forecast

Forecast

Consensus (5 analysts)

none

Avg. price target

$13.62+8302.22%

  • Strong buy 1
  • Buy 3
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $24.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.21 vs $-0.35
Surprise
+40.00%

VNRX news

All VNRX news

VolitionRX peers

Health Care sector
VNRX peer companies
CompanyPrice% ChgMarket capCompare
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs VNRX
BMRABiomerica Inc.1.08-0.92%$4.97Mvs VNRX
CDIOCardio Diagnostics Holdings Inc.1.60-3.03%$4.74Mvs VNRX
QCLSQ/C Technologies Inc.0.2784-6.01%$2.40Mvs VNRX
VRAXVirax Biolabs Group Limited0.3319-12.89%$446.40Kvs VNRX
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs VNRX
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs VNRX
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs VNRX

Indexes, lists and sector

VolitionRX stock FAQ

What is VolitionRX's stock price today?

VNRX last traded at $0.1621 as of Nov 20, 4:00 PM EST, down 1.58% on the day. Prices are delayed at least 15 minutes.

Who is VolitionRX's CEO?

Mr. Cameron Reynolds MBA is the chief executive officer of VolitionRX Limited, which has about 57 employees.

What is the VNRX 52-week high?

The 52-week high for VNRX is $7.80 and the 52-week low is $0.1555. The stock is currently 97.9% below its high.

Compare VNRX